Amplifon's Q3: 150 Basis Points of Proof, Zero Basis Points of Market Clarity

Amplifon reported the September quarter on 29 October, and on every line it controls the numbers were strong. Organic growth of 3.6% came against what management called the highest comparison base of the year and was balanced across all three regions. Adjusted EBITDA margin rose 90 basis points, adjusted EBIT rose 150 basis points — €52m from €43m, a 22% absolute jump — and adjusted free cash flow more than doubled to €79m from €33m. Full-year outlook confirmed: organic growth above 3%, EBITDA margin improvement in the region of 100 basis points.

The interesting part of this call was not the delivery. It was the fog.

The market that dare not speak its name

CEO Enrico Vita began by effectively discrediting the industry data everyone else is using. “the available market data sell in rather than sell outs. And were positively impacted by an unusually concentrated wave of new product launches across manufacturers which took place almost simultaneously this year in Q3” — Enrico Vita, Chief Executive Officer · 2026-10-29. The product launch wave — Widex, GN, Demant all shipping new platforms in the same quarter — inflated the underlying market print to roughly 8% sell-in growth in the US, with the private-pay segment up 12% and the insurance channel down about 5%.

if you look at the private pay market, which was up 12%, I hardly believe that this was not driven significantly by the sell in activities from the manufacturers in relation with the launches... I do not want really to say something that I am not 100% sure in terms of underlying growth.

This matters because peers were telling the same street a different story — 6% to 7% market growth in Q3, with the manufacturer crowd guiding 4% to 5% structurally. Amplifon is sticking to a 3% reference market, the same number it gave in March: “I see that some of our suppliers have even a more positive view on the total market. I think that 3% is a fair assumption for 2026” — Enrico Vita, CEO · 2026-03-04. When a retailer with 230 fewer clinics tells you the wholesalers' sell-in data is a mirage, that is a genuine, company-unique claim — and there is no echo of it anywhere in the curated global tape, where the loud themes are AI infrastructure and data-center power, not consumer hearing care.

The softer tell is in the share language. In March, Vita was defiant when Veronika Dubajova pressed him on share: “I would answer with a definite, no. What I mean is that we are absolutely convinced that overall, we are performing at least in line with the market, if not better” — Enrico Vita, CEO · 2026-03-04. In July the hedge appeared: most probably in line in France, slightly below estimates in Germany. On this call it hardened into something closer to a concession — “Most probably, we did not perform in line with the market in Germany” — Enrico Vita, Chief Executive Officer · 2026-10-29 — alongside faint praise for Italy, Spain, Australia and China, and a notable refusal to quantify US share at all for the quarter, only for the nine-month period. That progression, from certainty to feeling, is the real content of the quarter.

Fit for Growth: from revenue drag to margin engine

The Fit for growth program was again the single highest-ranked theme for this company, and the mechanics have rotated. In Q3 it subtracted 3.9% from revenue — the UK and India divestitures, the terminated US managed-care agreement, and roughly 230 clinic closures since launch, 30 of them in the quarter. The full-year drag was confirmed at about 3.5%, slightly heavier in Q4. That is exactly what was guided in July, so no news there.

What is new is where the benefit now lands. Rents sit below the EBITDA line under IFRS 16, and depreciation is falling as prior IT capex cycles complete and capex itself is cut — D&A excluding PPA fell about €2m year-on-year in the quarter. That is why EBIT margin expanded 150 basis points against 90 at EBITDA: “we have to take into account that the Fit for Growth also had an impact on rents, now according to the new IFRS are below the EBITDA margin, but of course, they are profitability at EBIT level” — Enrico Vita, Chief Executive Officer · 2026-10-29. The Americas margin is the one soft spot — up only 70 basis points to 21.4% and down sequentially — which the CEO attributed to the simple correlation between lower organic growth and profitability, plus the 40-store Louisiana franchisee acquisition closed in August that dilutes percentage margin. At 1.85x pro forma net debt to EBITDA, down from 1.92x in December, the deleveraging path is doing what it was designed to do.

GN Hearing: a clock, not a strategy

The GN Hearing acquisition has become a waiting game. The transaction was formally filed with European competition authorities in early October, clearances are in hand elsewhere, and management now says closing lands by year-end — “I also wanted to emphasize once again that we expect the closing by the end of the year. And I can definitely confirm that. So there are now only eventually few weeks to wait” — Enrico Vita, Chief Executive Officer · 2026-10-29. Both Julien Ouaddour and Oliver Metzger pushed hard on why nothing is being pre-positioned: no procurement shift, no inventory rundown of non-GN product, no acceleration of white label brand allocation. The answer is legalistic and repeated verbatim across three consecutive calls — the two companies remain separate until closing.

On the constraint that matters, Vita was direct: existing contractual obligations with the other four big manufacturers “will not prevent us to achieve the synergies in line with our assumptions that we have already shared with you” — Enrico Vita, Chief Executive Officer · 2026-10-29. Note what is missing: any quantification of the insourcing ramp, any 2027 margin framework, any comment on GN's own competitive position after a launch cycle in which it was widely seen as lagging. Everything is deferred to a Capital Markets Day next spring.

The Q4 ask

The arithmetic is uncomfortable in a way the headline is not. Nine-month EBITDA margin improvement is 80 basis points; the full-year guide is 100. Q4 — the biggest quarter of the year — therefore has to deliver well north of 150 basis points, which is precisely what Dubajova put to management and precisely what she did not get a number for beyond execution and the Fit for Growth continuation. Nine-month organic growth of 3.5% against an above-3% guide implies either conservatism or a Q4 slowdown, and Vita would only say he is “very confident about the fact that we can deliver a good organic growth in Q4, which might lead to a higher number than 3%” — Enrico Vita, Chief Executive Officer · 2026-10-29.

So: a mid-cap at roughly €2.8bn market value, cutting its way to a better P&L while waiting for a transformational deal to close, telling investors that the only clean read on demand arrives with the first-half data next year. The bull case is a margin story that does not need the market. The bear case is that the sell-in wave was a pull-forward, the share gains are narrower than advertised, and 2027 arrives with integration costs instead of a clean base. Amplifon has bought itself a quarter of credibility. It has not yet bought clarity.